Aaron D. Friedman, M.D.

Aaron D. Friedman, M.D.

Aaron D. Friedman, M.D.

Log into NorthShoreConnect

Profile

Conditions & Procedures

Conditions

Airway Disorders, Benign and Malignant Laryngeal Tumors, Dysplasia, Recurrent Respiratory Papillomatosis, Spasmodic Dysphonia, Swallowing Disorders, Vocal Cord Cancer, Vocal Cord Paralysis, Voice Disorders

Procedures

Care of the Performing/Professional Voice, Laryngeal Botox Injections, Laser Surgery of the Larynx, Vocal Cord Injections for Paralysis

General Information

Gender

Male

Affiliation

NorthShore Medical Group

Academic Rank

Clinical Assistant Professor

Languages

English

Board Certified

Otolaryngology

Clinical Service

Education, Training & Fellowships

Medical School

Columbia University College of Physicians & Surgeons, 2002

Internship

Cleveland Clinic, 2003

Residency

Cleveland Clinic, 2008

Fellowship

Massachusetts General Hospital/Center for Laryngeal Surgery, 2009

Locations

A

NorthShore Medical Group

501 Skokie Blvd.
Northbrook, IL 60062
847.504.3300 847.504.3305 fax Get Directions This location is wheelchair accessible.
B

NorthShore Medical Group

1000 Central St.
Suite 800
Evanston, IL 60201
847.504.3300 847.504.3305 fax Get Directions This location is wheelchair accessible.

Insurance

For behavioral health services, please confirm participation with your insurance company or provider.

2017 Exchange Plans (Individuals)

 
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
Ambetter Insured By Celtic
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
 
 
 
Blue Cross Blue Shield Blue Basic PPO A Multi-State Plan
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
 
 
 
Blue Cross Blue Shield Blue Choice Preferred PPO (All Plans)
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
 
 
 
Blue Cross Blue Shield Blue FocusCare HMO
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
 
 
 
Blue Cross Blue Shield Blue Precision HMO (All Plans)
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
Blue Cross Blue Shield Blue Premier PPO A Multi-State Plan
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
 
 
 
Blue Cross Blue Shield Blue Solution PPO A Multi-State Plan
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
 
 
 
Blue Cross Blue Shield BlueCare Direct with Advocate HMO
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
 
 
 
Cigna Connect HMO
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
 
 
 
Cigna Connect HSA
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
 
 
 

Off Exchange Plans (Individuals)

 
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
Aetna Bronze Deductible Only HSA Eligible Savings Plus OAMC PD
Not Available In 2017
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
Aetna Leap Everday Value Plan
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
 
 
 
Aetna Leap Everyday Carelink Centegra Health System
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
 
 
 
Aetna Savings Plus OAMC PD (All Metal Tiers)
Not Available In 2017
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
Aetna Whole Health Chicago (All Metal Tiers)
Not available for 2017
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
Aetna Whole Health Chicago Bronze Deductible Only HSA Eligible
Not available for 2017
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
Ambetter Insured By Celtic
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
 
 
 
Blue Cross Blue Shield Blue Choice Preferred PPO (All Plans)
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
 
 
 
Blue Cross Blue Shield Blue Choice Preferred Security PPO 100
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
 
 
 
Blue Cross Blue Shield Blue Cross Blue Premier 101 Multi-State Plan
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
 
 
 
Blue Cross Blue Shield Blue Cross Blue Shield Basic 103 Multi-State Plan
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
 
 
 
Blue Cross Blue Shield Blue Precision HMO (all plans)
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
Blue Cross Blue Shield Blue Precision Platinum HMO 104
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
Blue Cross Blue Shield BlueCare Direct with Advocate
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
 
 
 
Blue Cross Blue Shield Solution 102 Multi-State Plan
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
 
 
 
Coventry $15 Copay: Silver & Gold
Not Available In 2017
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
Coventry Bronze $10 Copay Carelink St. John's
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
 
 
 
Coventry Bronze $15 Copay Carelink St. John's
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
 
 
 
Coventry Bronze $20 Copay
Not Available In 2017
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
Coventry Bronze Deductible Only HSA Eligible
Not Available In 2017
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
Harken Health - an Affiliate of United Healthcare
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
 
 
 
Health Alliance HMO (All Metal Tiers)
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
 
 
 
Health Alliance POS (All Metal Tiers)
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
 
 
 
Health Alliance PPO (All Metal Tiers)
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
 
 
 
Humana Chicago HMOx (All Metal Tiers)
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
 
 
 
Humana Illinois HMOx
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
 
 
 
United Health One Golden Rule
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
United Healthcare Compass (All Plans)
Not Available In 2017
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
 
 
 

Employer Sponsored Plans

 
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
Aetna Choice POS II
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
Aetna Health Network Only
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
Aetna HMO
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
Aetna Managed Choice
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
Aetna Network Options
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
Aetna Open Access Aetna Select
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
Aetna Open Access Managed Choice
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
Aetna Open Choice PPO
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
Aetna Savings Plus
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
Aetna Select
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
Aetna Sub- Cofinity
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
Aetna Sub- First Health
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
Aetna Traditional Choice-Indemnity Plan
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
Aetna Whole Health Chicago (All Metal Tiers)
For employers with 2-50 employees
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
Beechstreet PPO Network
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
Blue Cross Blue Shield Blue Advantage HMO
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
Blue Cross Blue Shield Blue Choice Options
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
 
 
 
Blue Cross Blue Shield Blue Choice Preferred PPO (All Plans)
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
 
 
 
Blue Cross Blue Shield Blue Choice Select PPO
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
 
 
 
Blue Cross Blue Shield Blue Choice Select Value Choice
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
 
 
 
Blue Cross Blue Shield Blue Distinction Total Care Benefit Differentail
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
Blue Cross Blue Shield Blue Options (All Metal Tiers)
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
 
 
 
Blue Cross Blue Shield Blue PPO (All Metal Tiers)
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
Blue Cross Blue Shield Blue Precision HMO Plans (All Metal Tiers)
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
Blue Cross Blue Shield BlueCare Direct (All Metal Tiers)
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
 
 
 
Blue Cross Blue Shield BlueEdge HSA and BlueEdge HCA
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
Blue Cross Blue Shield BluePrint
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
Blue Cross Blue Shield Community Participating Option
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
Blue Cross Blue Shield HMOI
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
Blue Cross Blue Shield PPO
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
Blue Cross Blue Shield PPO Value Choice
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
Cigna Exclusive Provider Organization EPO
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
Cigna Great West Healthcare (GWH) Cigna Network
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
Cigna HMO
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
Cigna HMO Open Access
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
Cigna HMO Open Access POS
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
Cigna HMO POS
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
Cigna Medical PPO
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
Cigna Medical Indemnity
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
Cigna Medical LocalPlus
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
Cigna Medical LocalPlus In-Network
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
Cigna Medical Network
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
Cigna Medical Network POS
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
Cigna Medical Open Access Plus (OAP)
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
Cigna Medical Open Access Plus (OAP) In-Network
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
Cigna Medical Open Access POS
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
Cofinity PPO (an Aetna Company)
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
Coventry Consumer Choices (C3)
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
Coventry HMO
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
Coventry POS
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
Coventry PPO
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
Galaxy Health Network
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
Harken Health
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
Health Alliance HMO, PPO, POS, POS-C
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
 
 
 
Health Link HMO
If Unicare Affiliate logo present on card
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
Health Link PPO
If Unicare Affiliate logo present on card
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
Health Link-Open Access I, II, III
If Unicare Affiliate logo present on card
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
Healthcare's Finest Network- FHN 10 & 20
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
Healthcare's Finest Network- FHN Platinum
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
Healthcare's Finest Network- HFN Community Health Connect
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
Healthcare's Finest Network- HFN Community Health Connect Elite
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
Healthcare's Finest Network- HFN Community Health Connect Premiere
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
Healthcare's Finest Network- HFN-ID
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
Humana Advocate Centered EPO
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
 
 
 
Humana Advocate Centered HMO
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
 
 
 
Humana Choice POS
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
Humana Classic Plan (Traditional Indemnity Plan)
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
Humana Coinsurance: NPOS
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
Humana Coinsurance: PPO
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
Humana Coinsurance:HMO
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
Humana Condell Custom PPO
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
 
 
 
Humana Copay: HMO
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
Humana Copay: NPOS
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
Humana Copay: PPO
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
Humana COT National POS-Open Access
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
Humana Edward- Elmhurst Value HMO
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
 
 
 
Humana Edward-Elmhurst Advantage HSA/Choice PPO
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
 
 
 
Humana High-deductible plans (HDHP) HMO
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
Humana High-deductible plans (HDHP) National point of service (NPOS)
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
Humana High-deductible plans (HDHP) PPO
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
Humana Illinois Coordinated Care
Available In 2017
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
Humana Level Funded Premium
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
Humana NorthShore Complete Care
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
Humana Self Funding: Administrative Services Only (ASO)
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
Humana Self-Funding: Level Funded Premium (LFP)
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
Humana Self-Funding: Minimum Premium (MP)
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
Humana Self-Funding: Stop Loss Insurance
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
Humana Simplicity (HMO, POS, PPO)
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
Humana Total Health (100 or more employees)
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
Multiplan/ PHCS- Health EOS Network
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
 
 
 
Multiplan/ PHCS- MultiPlan Complementary
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
Multiplan/ PHCS- MultiPlan Limited Benefit Plan
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
Multiplan/ PHCS- MultiPlan Practitioner Only
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
Multiplan/ PHCS- MultiPlan Shared Savings
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
 
Multiplan/ PHCS- PHCS Healthy Directions
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
Multiplan/ PHCS- PHCS Practitioner Only
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
Multiplan/ PHCS- PHCS Savility
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
Multiplan/ PHCS- ValuePoint by MultiPlan
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
 
 
 
NorthShore Employee Network
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
Preferred Network Access
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
 
 
 
Preferred Plan- HealthSmart Get Better
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
Preferred Plan PPO
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
Stratose- National Preferred Provider Network
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
 
 
Three Rivers Provider PPO Network (TRPN)
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
UniCare HMO
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
 
 
UniCare HMO Performance Select
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
Unicare PPO
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
UniCare Travel Access
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
United Health One Golden Rule
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
United Healthcare Catalyst
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
United Healthcare Charter
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
 
 
 
United Healthcare Choice
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
United Healthcare Choice Plus
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
United Healthcare Core
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
 
 
 
United Healthcare Heritage
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
United Healthcare Multi-Choice
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
United Healthcare Navigate and Navigate Plus
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
 
 
 
United Healthcare Options Non-Differential PPO
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
United Healthcare Options PPO
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
United Healthcare Tiered Benefits
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
 
 
 

Medicaid

 
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
Aetna Better Health FHP
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
 
Aetna Better Health ICP
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
 
Blue Cross Blue Shield Community FHP
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
 
 
 
Blue Cross Blue Shield Community ICP
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
 
 
 
Cigna HealthSpring ICP
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
 
 
 
Community Care Alliance- ICP
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
 
 
 
Family Health Network- FHP
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
 
Harmony/WellCare FHP Plan
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
 
 
Humana ICP
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
 
 
 
Illinicare Family Health Plan (FHP/ACA)
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
 
 
 
Illinicare ICP
Primary Care- Current Patients Only
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
Illinois Department of Public Aid (IDPA)
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
Meridian FHP/ACA Expansion
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
Meridian ICP
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
 
 
 
Molina ICP
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
 
 
 
Next Level ACA/FHP
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
 
 
 

Medicare Advantage Plans

 
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
Aetna Medicare (SM) Plan (HMO)
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
Aetna Medicare (SM) Plan (PPO)
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
Aetna Medicare Advantage Group Plans
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
Aetna Medicare Connect Plus (PPO)/PPO Connect Plus
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
Aetna Medicare Standard Plan (PPO)/PPO Standard Plan
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
Aetna Medicare Value Plan (HMO)/HMO Value
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
Aetna Medicare Value Plan (PPO)/PPO Value Plan
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
Aetna Traditional Choice Plan
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
Blue Cross Blue Shield Medicare Advantage Basic HMO
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
 
 
 
Blue Cross Blue Shield Medicare Advantage Basic Plus HMO-POS
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
 
 
 
Blue Cross Blue Shield Medicare Advantage Choice Plus PPO
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
Blue Cross Blue Shield Medicare Advantage Choice Premier PPO
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
Blue Cross Blue Shield Medicare Advantage Premier Plus HMO-POS
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
 
 
 
Cigna-HealthSpring Advantage HMO
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
Cigna-HealthSpring Premier HMO-POS
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
Cigna-HealthSpring Primary HMO
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
Cigna-HealthSpring TotalCare HMO-SNP
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
Community Care Alliance Complete HMO-D-SNP
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
 
 
 
Community Care Alliance HMO
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
 
 
 
Harmony/WellCare Access (HMO-SNP)
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
 
 
 
Harmony/WellCare Choice (HMO-POS)
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
 
 
 
Harmony/WellCare Health Plan
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
 
 
 
Harmony/WellCare RX (HMO)
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
 
 
 
Harmony/WellCare Value (HMO-POS)
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
 
 
 
Harmony/WellCare-Medicare HMO Plans
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
 
 
 
Harmony/WellCare-Medicare Special Needs Plans
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
 
 
 
Humana Choice PPO
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
Humana Community HMO Diabetes and Heart (SNP Program)
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
Humana Gold Plus HMO
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
Humana Gold Plus PFFS
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
Meridian Medicare Advantage
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
 
 
 
Molina Medicare Advantage
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
 
 
 
United Healthcare - AARP Medicare Complete
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
United Healthcare AARP Medicare Complete Access
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
 
 
 
United Healthcare- AARP Medicare Complete Plus (HMO-POS)
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
United Healthcare Medicare Advantage Focus
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
 
 
 
United Healthcare- Medicare Solutions/Medicare Advantage
PRIMARY CARE
SPECIALTY CARE
HOSPITALS

Medicare Medicaid Alignment Initiative (MMAI) Plans

 
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
Aetna Better Health MMAI
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
 
 
 
Blue Cross Blue Shield Community MLTSS/LTSS
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
 
 
 
Blue Cross Blue Shield Community MMAI
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
Cigna-HealthSpring MMAI
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
Humana MMAI
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
Illinicare MLTSS/LTSS
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
 
 
 
Illinicare MMAI
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
Meridian MMAI
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
Molina MMAI
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
 
 
 

Medicare Supplemental Plans

 
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
Medicare Supplemental Plans
These plans are secondary to Traditional Medicare; we accept all supplemental plans. Please confirm your coverage benefits with your supplemental carrier.
PRIMARY CARE
SPECIALTY CARE
HOSPITALS

Coverage For Active Military

 
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
TRICARE For Life
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
 
 
TRICARE Prime
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
 
 
TRICARE Prime Overseas
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
 
 
TRICARE Prime Remote
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
 
 
TRICARE Prime Remote Overseas
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
 
 
TRICARE Reserve Select
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
 
 
TRICARE Retired Reserve
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
 
 
TRICARE Standard and Extra
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
 
 
TRICARE Standard Overseas
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
 
 
TRICARE US Family Plan
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
 
 
TRICARE Young Adult
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
 
 

Publications

  • Paradoxical Vocal Cord Motion in Pediatric Patients.

    Pediatric annals 2016 May 01

    Authors: Palla J, Friedman AD
    Abstract
    Paradoxical vocal cord motion (PVCM), also termed vocal cord dysfunction, is a poorly understood disorder of episodic dyspnea characterized by inappropriate vocal cord adduction during inspiration and potentially during expiration. It can coexist or be confused with asthma, so appropriate diagnosis is key to optimizing treatment success. Although many patients with PVCM may have underlying psychologic issues, there is emerging evidence to suggest that this entity is not psychogenic in every patient. Both laryngeal irritants and exercise have been identified as additional contributing factors in PVCM. Diagnosis of PVCM requires awake laryngoscopic confirmation. However, many patients do not exhibit signs of PVCM during this examination, despite provocation during testing. Therefore, clinical history remains key in determining which patients should proceed with behavioral therapy under the guidance of a speech pathologist. In addition, treatment may include limiting patient exposure to potential sources of laryngeal irritation. Refractory patients may benefit from psychologic assessment and treatment. [Pediatr Ann. 2016;45(5):e184-e188.].
    PMID: 27171808 [PubMed - as supplied by publisher]
  • Bedside Injection Medialization Laryngoplasty in Immediate Postoperative Patients.

    Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery 2015 Dec

    Authors: Barbu AM, Gniady JP, Vivero RJ, Friedman AD, Burns JA
    Abstract
    The morbidity of glottic insufficiency resulting from unilateral vocal fold immobility may significantly compromise postoperative recovery in patients with decreased pulmonary reserve or inability to protect their airway. Injection medialization laryngoplasty is an effective means of treating glottic insufficiency due to unilateral vocal fold immobility. The purpose of this study is to present our experience with bedside transoral injection medialization laryngoplasty in the immediate postoperative period.
    Case series with chart review.
    Academic tertiary care hospital.
    Patient demographics, clinical characteristics, procedural details, and short-term outcome measures of oral intake were recorded in a cohort of 68 patients over 5 years with unilateral vocal cord paralysis who underwent injection medialization as a bedside procedure in the immediate postoperative period.
    Mean time to injection was 8.2 days postoperatively. At the time of injection, 40 of 68 patients were nil per os. Seventy percent (28 of 40) had their diet advanced to adequate oral intake within 5 days of injection. Greater than half of the injections (36 of 68) were performed in the intensive care unit. No complications were noted, and all patients in this cohort were able to tolerate the bedside injection.
    Bedside injection medialization laryngoplasty in the immediate postoperative period via the transoral approach can be performed in patients, even in the intensive care unit, while on anticoagulation, and may be of benefit for hospitalized patients with unilateral vocal fold immobility. Further studies quantifying improvement in voice and swallowing data are merited.
    PMID: 26307574 [PubMed - as supplied by publisher]
  • Effect of mandibular tori on glottic exposure during simulated suspension microlaryngoscopy.

    The Annals of otology, rhinology, and laryngology 2014 Mar

    Authors: Best SR, Kobler JB, Friedman AD, Barbu AM, Zeitels SM, Burns JA
    Abstract
    Mandibular tori have been identified as a contributing factor in difficult exposure during intubation. However, no investigation has measured the effect of mandibular tori on glottic exposure during suspension microlaryngoscopy (SML). The objective of this study was to measure how the size and location of mandibular tori affect glottic exposure during simulated SML at different thyromental distances.
    Suspension microlaryngoscopy was modeled on an anatomically accurate skull and larynx with thyromental distances between 6 and 12 cm. Mandibular tori were simulated by protruding screws 5 to 15 mm from the lingual aspect of the mandible. The tori were positioned either 15 mm (anterior) or 25 mm (posterior) from the midline of the symphysis. The glottic exposure for the various-size tori in each location was measured by recording the displacement of the glottiscope tip relative to the most anterior exposure achievable without tori. The glottiscope angle relative to the horizontal plane was measured for each condition.
    Mandibular tori of more than 10 mm had a significant impact on glottic exposure. Displacement of the glottiscope tip ranged from 2 to 9 mm for anteriorly placed tori and from 7 to 29 mm for posteriorly placed tori, with larger tori causing greater displacement. Increasing the thyromental distance increased the posterior glottiscope tip displacement regardless of torus size or location. The glottiscope angle increased with larger tori (12º to 28º), but this angle did not change with increasing thyromental distance.
    Larger size and more-posterior location of mandibular tori more significantly reduce glottic exposure during SML. The inner table of the mandible is the most relevant anatomic constraint on glottic exposure, which varies with the presence or absence of mandibular tori independent of thyromental distance.
    PMID: 24633945 [PubMed - as supplied by publisher]
  • Salvage endoscopic angiolytic KTP laser treatment of early glottic cancer after failed radiotherapy.

    The Annals of otology, rhinology, and laryngology 2013 Apr

    Authors: Barbu AM, Burns JA, Lopez-Guerra G, Landau-Zemer T, Friedman AD, Zeitels SM
    Abstract
    Management of early glottic cancer subsequent to failed radiotherapy is challenging, especially in balancing oncological control and function preservation. Patients frequently have been incentivized against surgical management and thus have undergone radiotherapy as initial treatment. This history compounds the difficulty of discussions about surgical management after recurrence. Typically, endoscopic salvage has less morbidity than transcervical partial laryngectomy and is clearly desirable over total laryngectomy. However, there are appropriate concerns about the efficacy of endoscopic salvage and the overarching impact on larynx preservation and survival. Given our success with endoscopic angiolytic KTP laser treatment of previously nonirradiated T1 and T2 glottic cancers, we examined our results from treating similar-sized lesions after failed radiotherapy.
    We performed a retrospective chart review of 20 patients from our cancer database who had undergone failed radiation therapy elsewhere for early glottic cancer and then underwent endoscopic angiolytic KTP laser treatment.
    Analysis of the geographic tumor recurrence of the 20 patients revealed T1a N0 M0 cancer in 4 patients, T1b N0 M0 cancer in 1 patient, T2a N0 M0 cancer in 1 patient, and T2b N0 M0 cancer in 14 patients. After KTP laser salvage treatment, 4 patients (20%) had local recurrence (all T2b) and required subsequent total laryngectomy, and 3 of these patients (15%) ultimately died of disease. The remaining 16 patients (80%) were free of disease at least 2 years after endoscopic salvage (average follow-up, 39 months).
    Our investigation provides preliminary evidence that angiolytic KTP laser salvage treatment of early glottic cancer is an effective treatment after failed irradiation. Studies with larger cohorts and longer follow-up will be necessary to establish incontrovertible evidence of its efficacy.
    PMID: 23697320 [PubMed - as supplied by publisher]
  • Voice outcomes for photoangiolytic KTP laser treatment of early glottic cancer.

    The Annals of otology, rhinology, and laryngology 2013 Mar

    Authors: Friedman AD, Hillman RE, Landau-Zemer T, Burns JA, Zeitels SM
    Abstract
    Surgery and radiotherapy routinely provide high cure rates in treating early glottic cancer. Therefore, key metrics for success are optimal voice outcome and preservation of future cancer treatment options. Remarkably, there is a paucity of pretreatment versus posttreatment voice outcome data. Angiolytic KTP (potassium titanyl phosphate) laser treatment of early glottic cancer with ultranarrow margins was initiated to better preserve vocal function. Given that effective oncological results have been achieved, it was hypothesized that this approach would also result in improved posttreatment measures of vocal function that more closely approximate historical norms than pretreatment values.
    Pretreatment and posttreatment voice outcome data were obtained for 92 patients (64 with T1 cancer and 28 with T2 cancer) who underwent 532-nm KTP laser treatment of early glottic cancer in a study design in which each patient essentially served as his or her own control. The evaluations included objective measures (acoustic and aerodynamic) and patients' self-assessments of vocal function (Voice-Related Quality of Life; V-RQOL). A series of mixed analyses of variance were conducted for all vocal function measures, with tumor stage and depth of invasion as the between-subjects variables and time (presurgery versus postsurgery) as the within-subject variable.
    There were statistically significant (p < or = 0.05) postoperative improvements for acoustic (perturbation and noise-to-harmonics ratio) and aerodynamic (subglottic pressure and vocal efficiency) measures of vocal function, as well as for V-RQOL assessment.
    Comprehensive pretreatment and posttreatment voice measures in a large patient cohort demonstrated that the KTP laser significantly improved postoperative vocal function in patients with early glottic cancer. Furthermore, radiotherapy was preserved as an oncological treatment option.
    PMID: 23577566 [PubMed - as supplied by publisher]
  • High-force simulated intubation fails to dislocate cricoarytenoid joint in ex vivo human larynges.

    The Annals of otology, rhinology, and laryngology 2012 Nov

    Authors: Friedman AD, Kobler JB, Landau-Zemer T, Barbu AM, Burns JA
    Abstract
    We assessed the likelihood of arytenoid dislocation during intubation through the application of controlled force.
    Six cadaveric human larynges were mounted in an apparatus for simulating forcible collision with the arytenoid complexes. An endotracheal tube tip probe (ETTP) was used to push one arytenoid complex, and a non-slip probe (NSP) was tested on the other. Increasing pressure was applied until the probes either slipped or reached 5 kg of force. Dissection was then performed to assess the integrity of the cricoarytenoid ligament. The forces obtained by pushing an endotracheal tube against an electronic balance were measured to estimate the maximal possible intubating force.
    None of the ETTP or NSP trials disrupted the cricoarytenoid joint ligaments, and the joint never appeared to be dislocated. The mean maximal forces were 1.8 kg for the ETTP (after which, slippage consistently occurred) and 4.7 kg for the NSP. The mean maximal forces from an endotracheal tube pushed against a scale were 1.5 kg (without stylet) and 4.6 kg (with stylet).
    Arytenoid dislocation did not happen, and gross disruption of the joint capsule or ligament did not occur, even when the testing approximated the maximum force achievable under extreme conditions. Endotracheal tube insertion thus seems unlikely to cause arytenoid dislocation.
    PMID: 23193908 [PubMed - as supplied by publisher]
  • Safety and dosing of bevacizumab (avastin) for the treatment of recurrent respiratory papillomatosis.

    The Annals of otology, rhinology, and laryngology 2012 Sep

    Authors: Best SR, Friedman AD, Landau-Zemer T, Barbu AM, Burns JA, Freeman MW, Halvorsen YD, Hillman RE, Zeitels SM
    Abstract
    Increasing evidence supports the use of laryngeal injections of the antiangiogenic agent bevacizumab (Avastin) for the adjuvant treatment of recurrent respiratory papillomatosis (RRP). A recent prospective open-label investigation, approved by the US Food and Drug Administration, employing 12.5 mg of sublesional bevacizumab demonstrated single-site efficacy without complications; however, the safety of multiple-site injections and higher dosing has not yet been reported. The primary objective of this study was to report on the safety of increased doses of bevacizumab for the treatment of RRP.
    Two cohorts of adult patients were evaluated. In the first group, a prospective analysis was performed on patients with a diagnosis of laryngeal RRP after t heir participation in th e initial clinical trial with a single-site lowerdose (7.5 to 12.5 mg). They received higher doses of sublesional laryngeal bevacizumab (15 to 50 mg total) with detailed physiologic, hematologic, and serum chemistry measurements performed before and after each bevacizumab injection. A second cohort of patients received sublesional laryngeal injections of bevacizumab (15 to 88 mg total) without physiologic measurements and underwent a retrospective analysis of reported complications.
    One hundred consecutive laryngeal injection sessions (office, 87; operating room, 13) with bevacizumab were performed in 43 patients, with a mean dose of 30 mg total per treatment (range, 15 to 88 mg). Sixty-three of the 100 sessions were accompanied by KTP laser photoangiolysis of the papilloma prior to bevacizumab injections. Eighteen patients (cohort 1) underwent detailed physiologic assessment, and no dysfunction was observed. There were no local or systemic complications of bevacizumab administration. The second group of 25 patients (cohort 2) also reported no significant local or systemic complications. Neither patient group was observed to have a local wound problem in the larynx.
    This investigation provides evidence that higher doses of bevacizumab are relatively safe in adult patients with laryngeal RRP. Further refinements in pharmacologic concentration and drug delivery will determine the optimal treatment regimens in the future.
    PMID: 23012897 [PubMed - as supplied by publisher]
  • High-speed videoendoscopic analysis of relationships between cepstral-based acoustic measures and voice production mechanisms in patients undergoing phonomicrosurgery.

    The Annals of otology, rhinology, and laryngology 2012 May

    Authors: Mehta DD, Zeitels SM, Burns JA, Friedman AD, Deliyski DD, Hillman RE
    Abstract
    There is increased interest in using cepstral-based acoustic measures for objective clinical voice assessment because of their apparent advantages over more time-honored methods, but there is a paucity of information about how these newer measures relate to underlying phonatory mechanisms.
    We investigated the relationships between the acoustic cepstral peak magnitude (CPM) and high-speed videoendoscopy (HSV)-based measures of vocal fold phonatory function in 20 subjects who underwent phonomicrosurgery for vocal fold lesions. Acoustic and imaging data were acquired during sustained vowel phonation before and after surgery.
    The changes in the measures between presurgical and postsurgical assessments showed that the CPM correlated significantly with an HSV-based measure combining fundamental frequency deviation and average speed quotient (r = 0.70; p < 0.001) in a multiple linear regression, and that the variation in the CPM could also be attributed to trading relationships between the HSV-based measures of vibratory phase asymmetry and glottal closure.
    These initial results demonstrate that the clinical utility of cepstral-based measures can be enhanced by a better understanding of how these acoustic measures relate to underlying phonatory mechanisms. The CPM seems to integrate information about aperiodicity in vocal fold vibration, the relative speed of glottal closure, and estimates of glottal noise generation.
    PMID: 22724281 [PubMed - as supplied by publisher]
  • Submucosal neoplasms of the laryngeal introitus.

    The Journal of laryngology and otology 2012 Jul

    Authors: Friedman AD, Burns JA, Lutch MJ, Zeitels SM
    Abstract
    The differential diagnosis of endolaryngeal mesenchymal neoplasms includes a wide spectrum of benign and malignant pathologies, which have been rarely photo-documented and assessed as a group.
    Non-epithelial neoplasms of the endolarynx seen at our centre from 2002 to 2011 (n = 38; 36 treated at our institution) were retrospectively reviewed, with attention to clinical presentation, radiographic imaging, operative management, histology, and pre- and post-operative endoscopy. Submucosal squamous cell carcinomas, mucosal cysts, amyloid and Teflon granulomas were excluded.
    Twenty-three of a total of 36 patients underwent definitive endoscopic surgical treatment. Supraglottic pathologies included lymphoma, lipoma, neuroendocrine carcinoma, lymphangioma, oncocytoma, haemangioma, synovial cell sarcoma and benign spindle cell neoplasm. Transglottic pathologies included synovial cell sarcoma and granular cell tumour. Glottic pathologies included granular cell tumour, osteoma, rhabdomyoma, rhabdomycosarcoma and myofibroblastic sarcoma. Subglottic pathologies included chondrosarcoma, neurofibroma, adenoid cystic carcinoma and vascular malformation.
    The site of origin, degree of malignant behaviour and sensitivity to adjuvant treatment determined the course of surgical management, i.e. endolaryngeal versus transcervical, and limited removal versus wider resection.
    PMID: 22624973 [PubMed - as supplied by publisher]
  • Subepithelial vocal fold infusion: a useful diagnostic and therapeutic technique.

    The Annals of otology, rhinology, and laryngology 2012 Apr

    Authors: Burns JA, Friedman AD, Lutch MJ, Zeitels SM
    Abstract
    Preservation of the maximum amount of subepithelial superficial lamina propria (SLP) remains an important goal during microlaryngoscopic surgery of phonatory mucosa. Volume expansion of the SLP (Reinke's space) with subepithelial infusion of saline solution has been widely adopted since its introduction in 1991. This technique has evolved so that it is currently used to assist with determining the depth of vocal fold disease, defining residual pliable SLP, enhancing microsurgical precision, and identifying unrecognized disease. The purpose of this investigation was to examine the indications, methods, and benefits of subepithelial infusion of saline solution as an adjunct technique during phonomicrosurgery.
    In a prospective case series, we collected data on 280 consecutive microlaryngoscopy procedures performed over a 12-month period. Subepithelial infusion of saline solution was included in 178 procedures.
    New disease was identified in 20 of the 178 patients (scar in 15, sulcus in 4, and a mucosal bridge in 1). The depth of needle placement varied depending on the specific disease: 118 of the 178 infusions were done just below the epithelial basement membrane, and 60 infusions were performed deeper within the SLP, just superficial to the vocal ligament. The infusion technique provided surgical assistance in multiple ways, including identifying residual SLP (130 patients), defining the SLP-lesion interface (65 patients), lifting scar (60 patients),providing tension for cordotomy (47 patients), expanding the SLP volume to protect against laser damage (45 patients), and providing hydrostatic compression of vascular ectasias or varices for photoangiolysis (7 patients). The microlaryngoscopy procedures during which infusion was not performed (102 of 280 procedures) were primarily for nonglottic cancer (46 patients), stenosis (30 patients), or arytenoid granuloma (13 patients).
    Subepithelial infusion of the SLP with saline solution is a useful microsurgical adjunct during diagnosis and treatment of phonatory mucosal lesions.
    PMID: 22606925 [PubMed - as supplied by publisher]

Social Media

Featured Videos

Karen Grigsby Scott shares her journey from fear to triumph over vocal cord cancer.

Karen Grigsby Scott shares her journey from fear to triumph over vocal cord cancer.

Hannah and her family discuss how Dr. Aaron Friedman and the NorthShore Voice Center helped restore her voice.

Hannah and her family discuss how Dr. Aaron Friedman and the NorthShore Voice Center helped restore her voice.

Dr. Aaron Friedman discusses the benefits of office-based laryngoplasty injections for vocal cord paralysis.

Dr. Aaron Friedman discusses the benefits of office-based laryngoplasty injections for vocal cord paralysis.

Dr. Aaron Friedman discusses the conditions treated at the NorthShore Voice Center.

Dr. Aaron Friedman discusses the conditions treated at the NorthShore Voice Center.

Dr. Aaron Friedman discusses the KTP laser and it's uses at the NorthShore Voice Center.

Dr. Aaron Friedman discusses the KTP laser and it's uses at the NorthShore Voice Center.